New hope for rare eye cancer that spreads to the liver
NCT ID NCT04935229
Summary
This early-stage study tested a new drug called SD-101, delivered directly to the liver, for adults with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if SD-101 was safe and tolerable when given alone or combined with standard immunotherapy drugs. Researchers aimed to find the best dose and see if the treatment could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA IN THE LIVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Stanford
Stanford, California, 94305, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Colorado
Denver, Colorado, 80045, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Washington University
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.